Results 191 to 200 of about 46,054 (219)
Some of the next articles are maybe not open access.
Interventional Cardiology Clinics, 2022
In-stent restenosis (ISR) remains a potential complication after percutaneous coronary intervention, even in the era of drug-eluting stents, and its treatment remains suboptimal. Neoatherosclerosis is an important component of the pathology of ISR and is accelerated in drug-eluting stents compared with bare-metal stents.
Kenji, Kawai+2 more
openaire +2 more sources
In-stent restenosis (ISR) remains a potential complication after percutaneous coronary intervention, even in the era of drug-eluting stents, and its treatment remains suboptimal. Neoatherosclerosis is an important component of the pathology of ISR and is accelerated in drug-eluting stents compared with bare-metal stents.
Kenji, Kawai+2 more
openaire +2 more sources
Interventional Cardiology Clinics, 2016
In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. The mean time from percutaneous coronary intervention (PCI) to ISR was 12 months with drug-eluting stents (DES) and 6 months with bare metal stents (BMS). ISR typically presents as recurrent angina. The use of DES has significantly reduced the rate of ISR compared with BMS.
Michael S. Lee, Gaurav Banka
openaire +5 more sources
In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. The mean time from percutaneous coronary intervention (PCI) to ISR was 12 months with drug-eluting stents (DES) and 6 months with bare metal stents (BMS). ISR typically presents as recurrent angina. The use of DES has significantly reduced the rate of ISR compared with BMS.
Michael S. Lee, Gaurav Banka
openaire +5 more sources
Management of in-stent restenosis
EuroIntervention, 2022In-stent restenosis (ISR) remains the most common cause of stent failure after percutaneous coronary intervention (PCI). Recent data suggest that ISR-PCI accounts for 5-10% of all PCI procedures performed in current clinical practice. This State-of-the-Art review will primarily focus on the management of ISR but will begin by briefly discussing ...
Alfonso, Fernando+4 more
openaire +2 more sources
Treatment of in-stent restenosis [PDF]
Since its introduction in 1977, percutaneous coronary intervention (PCI) has revolutionized the treatment of coronary artery disease by providing a safe and feasible alternative to coronary bypass graft (CABG) surgery [1]. The subsequent development of coronary stents has had a further positive impact on the clinical effectiveness and predictability of
Bernhard Meier, Thuraia Nageh
openaire +2 more sources
Stenting for in-stent restenosis
Catheterization and Cardiovascular Interventions, 2000Intravascular ultrasound studies have shown that additional stent implantation is the only percutaneous technique that allows for recovery of all the lumen area of the original implantation procedure. Despite this theoretical advantage, information on systematic additional stent implantation is still forthcoming, especially concerning the impact of new
Guia Moschi+7 more
openaire +3 more sources
Restenosis is an arterial wall healing response to mechanical injury at the site of a previously treated coronary segment. In-stent restenosis (ISR) is an angiographic diagnosis, defined as recurrent diameter stenosis >50% within a stent or at its edges (5 mm segments proximal and distal to the stent).
Roisin Colleran, Robert A. Byrne
openaire +1 more source
In-stent restenosis in vertebral artery stenting [PDF]
Sir, Tsutsumi et al. reported the clinical and angiographic data on 12 patients receiving stent deployment for symptomatic ostial vertebral artery (VA) stenosis [1]. The in-stent re-stenosis (ISR) rate was surprising low – 0% angiographic restenosis at 12 months and 8% after a mean of 31.5 months clinical/radiological follow-up.
Yen-Hung Lin, Hsien-Li Kao
openaire +2 more sources
Pathology of in-stent restenosis
Current Opinion in Lipidology, 1999The process of in-stent restenosis parallels wound healing responses. Stent deployment results in early thrombus deposition and acute inflammation, granulation tissue development, and ultimately smooth muscle cell proliferation and extracellular matrix synthesis.
Renu Virmani, Andrew Farb
openaire +3 more sources